Navigation Links
Anti-Mucus Drug Slows Symptoms of COPD
Date:6/12/2008

Carbocisteine reduced exacerbation of the lung condition by 25%, Chinese study says

THURSDAY, June 12 (HealthDay News) -- In people suffering from chronic obstructive pulmonary disease (COPD), the expectorant carbocisteine seems to help slow worsening of symptoms, Chinese researchers report.

COPD is a progressive, destructive disease of the lungs, usually brought on by smoking, for which there's no known cure. Symptoms include restricted breathing, secretion of mucus, oxidative stress and inflammation of the airway.

"COPD is a major respiratory disease that affects many people, especially the elderly, and the treatment of COPD is costly," said lead researcher Dr. Jin-Ping Zheng, of the Guangzhou Institute of Respiratory Disease in Guangzhou, China.

"Carbocisteine is a highly cost-effective medicine that prevents exacerbation of COPD," Zheng said.

Long-term use of carbocisteine can help preserve health-care resourses, Zheng said. "This is especially good for developing countries and low-income populations -- it provides an option to treat COPD," he said. "Carbocisteine, as well as other mucolytics, are old medicines. However, carefully conducted clinical trials of existing medications can offer new insights into COPD care."

The findings are in the June 15 issue of The Lancet.

For the study, 709 patients with COPD were randomly selected to receive daily doses of carbocisteine or placebo. Over the year of the study, patients receiving carbocisteine had a 25 percent reduction in the number of exacerbations of COPD, compared with patients receiving a placebo, the researchers found.

"In addition, quality of life was improved significantly," Zheng said, adding that long-term administration of mucolytics, such as carbocisteine, should be recognized as a worthwhile treatment for COPD.

Dr. Paul Scanlon, of the Mayo Clinic's Division of Pulmonary and Critical Care Medicine, said using a similar medication might be effective and less expensive than current COPD treatments in the United States.

"Results of the study are impressive and fairly convincing," said Scanlon. "The magnitude of reduction of the frequency of exacerbations of 25 percent is on a par with other drugs that we have, such as inhaled corticosteroids and long-acting beta agonists."

The question is, what would be the role of this drug in clinical practice in the United States, Scanlon said. He noted that drugs used in China and other parts of the world to treat COPD are different from the drugs used in United States.

"The drug works," Scanlon said. "But it has a role yet to be defined. If it has treatment effects on a par with inhaled corticosteroids and long-acting beta agonists, which are much more expensive, then carbocisteine has a role in developing countries and may have a role here," he said.

Dr. Neil Schachter, a professor of pulmonary medicine at Mount Sinai Medical Center in New York City, said it's not known whether carbocisteine could be used instead of other drugs. "Some of these drugs work additively when given together, so it might be even more effective in conjunction with some of the current therapies," he said. "However, whether it fills the roles that other drugs such as steroids or long-acting beta agonists fill is not clear."

More information

To learn more about COPD, visit the U.S. National Heart, Lung, and Blood Institute.



SOURCES: Jin-Ping Zheng, M.D., Guangzhou Institute of Respiratory Disease, Guangzhou, China; Paul D. Scanlon, M.D., Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minn.; Neil Schachter, M.D., professor of pulmonary medicine, Mount Sinai Medical Center, New York City; June 14, 2008, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Health Insurance Premium Growth Slows for Fourth Straight Year
2. Philanthropic Giving for Health Care Slows in 2006 in both U.S. and Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
3. Drug slows prostate tumor growth by keeping vitamin A active
4. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
5. Sorafenib Slows Growth of Some Leukemias
6. Targeting astrocytes slows disease progression in ALS
7. Viral Therapy Slows Pediatric Tumors in Mice
8. High zinc status in lung cells slows growth and induces DNA damage-induced gene expression
9. Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics
10. Lithium chloride slows onset of skeletal muscle disorder
11. Diabetes Drug Slows Clogging of Arteries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 2016 , ... For many years, Andrew G. Zubinas has accumulated ... beauty of the Lithuanian language and its poetry inspired him in writing ... lyrically explores all aspects of a living, breathing forest where nothing ever stays the ...
(Date:12/5/2016)... Atlanta, GA (PRWEB) , ... ... ... information technology and security executive networking and relationship-marketing firm, announced today that ... for the 2017 Information Security Executive® (ISE®) Central Awards. , Awards include ...
(Date:12/5/2016)... Novato, CA (PRWEB) , ... December 05, 2016 ... ... company, has extended its partnership with leading global lifestyle design firm kathy ireland® ... , Worldwise® and kathy ireland® Worldwide entered into an exclusive licensing agreement three ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive ... of L-Citrulline and glutathione to enhance production of nitric oxide (NO). , NitroGenesis ... shown to produce NO twice as effectively and sustains NO blood levels twice ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... announced that the company will provide alerting technology to Central Illinois Health ... awarded $1.7 million in federal funds as the sole sub-recipient participating with ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAKE OSWEGO, Ore. , Dec. 5, 2016 /PRNewswire/ ... in the BioInsight clinical study. The study evaluates the ... 2 insertion procedure in an office setting. ... ProMRI ® technology that is placed underneath a ... atrial fibrillation and syncope (fainting). Atrial fibrillation is a ...
(Date:12/5/2016)... and Gateway Health proudly announce a dynamic collaboration that will ... members with specific high risk needs. In an ... of consumers, Wellbridge combines technology and population expertise with a ... daily behaviors and lifestyle. ... , , "Dealing ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, ... Sankyo) today announced preliminary safety and efficacy data ... investigational oral selective MDM2 inhibitor, suggesting that DS-3032 ... including relapsed/refractory acute myeloid leukemia (AML) and high-risk ... escalation part of the phase 1 study of DS-3032 ...
Breaking Medicine Technology: